JP7241352B2 - 肺扁平上皮癌のサブタイピングのための方法 - Google Patents

肺扁平上皮癌のサブタイピングのための方法 Download PDF

Info

Publication number
JP7241352B2
JP7241352B2 JP2019512943A JP2019512943A JP7241352B2 JP 7241352 B2 JP7241352 B2 JP 7241352B2 JP 2019512943 A JP2019512943 A JP 2019512943A JP 2019512943 A JP2019512943 A JP 2019512943A JP 7241352 B2 JP7241352 B2 JP 7241352B2
Authority
JP
Japan
Prior art keywords
expression
classifier
sample
biomarker
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516406A5 (enExample
JP2019516406A (ja
Inventor
ハワジン ファルキ，
マイラ ライ－ゴールドマン，
グレッグ メイヒュー，
ジョナサン セロディー，
チャールズ ペロウ，
デイビッド ニール ヘイズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2019516406A publication Critical patent/JP2019516406A/ja
Publication of JP2019516406A5 publication Critical patent/JP2019516406A5/ja
Application granted granted Critical
Publication of JP7241352B2 publication Critical patent/JP7241352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
JP2019512943A 2016-05-17 2017-05-17 肺扁平上皮癌のサブタイピングのための方法 Active JP7241352B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662337645P 2016-05-17 2016-05-17
US62/337,645 2016-05-17
US201662379402P 2016-08-25 2016-08-25
US62/379,402 2016-08-25
US201662396587P 2016-09-19 2016-09-19
US62/396,587 2016-09-19
US201662420836P 2016-11-11 2016-11-11
US62/420,836 2016-11-11
US201662425717P 2016-11-23 2016-11-23
US62/425,717 2016-11-23
PCT/US2017/033107 WO2017201164A1 (en) 2016-05-17 2017-05-17 Methods for subtyping of lung squamous cell carcinoma

Publications (3)

Publication Number Publication Date
JP2019516406A JP2019516406A (ja) 2019-06-20
JP2019516406A5 JP2019516406A5 (enExample) 2020-06-25
JP7241352B2 true JP7241352B2 (ja) 2023-03-17

Family

ID=60325556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512943A Active JP7241352B2 (ja) 2016-05-17 2017-05-17 肺扁平上皮癌のサブタイピングのための方法

Country Status (6)

Country Link
US (2) US11041214B2 (enExample)
EP (1) EP3458611B1 (enExample)
JP (1) JP7241352B2 (enExample)
CN (1) CN109863251B (enExample)
CA (1) CA3024744A1 (enExample)
WO (1) WO2017201164A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149209B1 (en) 2014-05-30 2021-02-17 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
US12195805B2 (en) 2018-02-13 2025-01-14 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
WO2020076897A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
DE102018125324A1 (de) * 2018-10-12 2020-04-16 Universität Rostock Verfahren zur Vorhersage einer Antwort auf die Therapie von Krankheiten
WO2021041726A1 (en) * 2019-08-27 2021-03-04 Exact Sciences Development Company, Llc Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
CN111369501B (zh) * 2020-02-24 2022-04-01 武汉大学 一种基于视觉特征识别口腔鳞状细胞癌的深度学习方法
CN111653312B (zh) * 2020-05-28 2021-04-16 上海宝藤生物医药科技股份有限公司 一种利用基因组数据探究疾病亚型亲缘性的方法
CN111755073B (zh) * 2020-05-31 2022-11-15 复旦大学 基于转录组的pd-1疗法治疗效果预测系统
CN112433054A (zh) * 2020-11-20 2021-03-02 四川大学华西医院 C9蛋白检测试剂在制备肺癌筛查试剂盒中的用途
WO2022226391A1 (en) * 2021-04-23 2022-10-27 The Trustees Of Columbia University In The City Of New York Methods for detecting squamous cancer
CN115308418B (zh) * 2022-07-07 2024-11-08 翁良 一种生物标志物及其在肺鳞癌诊断中的应用
CN116129998B (zh) * 2023-01-19 2024-06-11 中国医学科学院肿瘤医院 一种食管鳞状细胞癌数据的处理方法及其系统
CN115982644B (zh) * 2023-01-19 2024-04-30 中国医学科学院肿瘤医院 一种食管鳞状细胞癌分类模型构建与数据处理方法
CN116287253B (zh) * 2023-02-22 2024-06-28 武汉科技大学 一种肺癌分子标志物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540672A (ja) 2007-10-09 2010-12-24 キュアバック ゲーエムベーハー 肺癌治療用、特に非小細胞肺癌（ｎｓｃｌｃ）治療用組成物
JP2015521480A (ja) 2012-06-18 2015-07-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 頭頸部癌予後に関する方法
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160109453A1 (en) 2013-05-24 2016-04-21 Ait Austrian Institute Of Technology Gmbh Lung Cancer Diagnostic Method and Means

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2002226912A1 (en) 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
JP2007006792A (ja) 2005-06-30 2007-01-18 Hitachi Software Eng Co Ltd 肺腺癌の胸膜浸潤を判別するための遺伝子セット
WO2008151110A2 (en) 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
CA2726531A1 (en) 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
CN101509035A (zh) 2008-09-05 2009-08-19 中国人民解放军总医院 肺癌分型的基因序列及其应用
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
EP3149209B1 (en) 2014-05-30 2021-02-17 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
CN107849613A (zh) 2015-04-14 2018-03-27 基因中心治疗公司 用于肺癌分型的方法
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
WO2019018764A1 (en) 2017-07-21 2019-01-24 Genecentric Therapeutics, Inc. METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540672A (ja) 2007-10-09 2010-12-24 キュアバック ゲーエムベーハー 肺癌治療用、特に非小細胞肺癌（ｎｓｃｌｃ）治療用組成物
JP2015521480A (ja) 2012-06-18 2015-07-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 頭頸部癌予後に関する方法
US20160109453A1 (en) 2013-05-24 2016-04-21 Ait Austrian Institute Of Technology Gmbh Lung Cancer Diagnostic Method and Means
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Matthew D Wilkerson，Clinical Cancer Res. ，2010年，16(19)，4864-75.
肺がんの新規免疫療法，免疫療法ニュースピックアップ，https://web.archive.org/web/20160313081253/https://www.gan-info.jp/dendritic/newspickup/article02/，[Online]，２０１６年３月１３日，［２０２１年6月9日検索］

Also Published As

Publication number Publication date
CN109863251B (zh) 2022-11-18
EP3458611A1 (en) 2019-03-27
US11041214B2 (en) 2021-06-22
US20210340631A1 (en) 2021-11-04
EP3458611B1 (en) 2023-11-08
WO2017201164A1 (en) 2017-11-23
CA3024744A1 (en) 2017-11-23
EP3458611A4 (en) 2020-02-26
US12139765B2 (en) 2024-11-12
JP2019516406A (ja) 2019-06-20
US20190338366A1 (en) 2019-11-07
CN109863251A (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
JP7241352B2 (ja) 肺扁平上皮癌のサブタイピングのための方法
JP7241353B2 (ja) 肺腺癌のサブタイピングのための方法
US12006554B2 (en) Methods for subtyping of head and neck squamous cell carcinoma
US20220243283A1 (en) Methods for typing of lung cancer
EP3149209B1 (en) Methods for typing of lung cancer
US11739386B2 (en) Methods for determining response to PARP inhibitors
US12195805B2 (en) Methods for subtyping of bladder cancer
EP4262984A2 (en) Methods for selecting and treating cancer with fgfr3 inhibitors
US20250191689A1 (en) Methods for subtyping and treatment of head and neck squamous cell carcinoma
HK40006869B (en) Methods for subtyping of lung squamous cell carcinoma
HK40006869A (en) Methods for subtyping of lung squamous cell carcinoma
HK40006868B (en) Methods for subtyping of lung adenocarcinoma
HK40006868A (en) Methods for subtyping of lung adenocarcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230227

R150 Certificate of patent or registration of utility model

Ref document number: 7241352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150